Genscript Biotech Management

Management criteria checks 2/4

Genscript Biotech's CEO is Weihui Shao, appointed in Jul 2021, has a tenure of 2.83 years. directly owns 0.021% of the company’s shares, worth HK$5.22M. The average tenure of the management team and the board of directors is 3.5 years and 7.1 years respectively.

Key information

Weihui Shao

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	0.02%
Management average tenure	3.5yrs
Board average tenure	7.1yrs

Recent management updates

Recent updates

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Dec 05

CEO

Weihui Shao (43 yo)

2.8yrs

Tenure

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 3.3m
Weihui Shao	CEO & COO	2.8yrs	no data	0.021% $ 5.2m
Ye Wang	Co-Founder	22.3yrs	US$615.00k	0.037% $ 9.0m
Shiniu Wei	Chief Financial Officer	3.4yrs	no data	no data
Fangliang Zhang	co-founder & Executive Director	1.4yrs	US$271.00k	no data
Li Zhu	Chief Strategy Officer & Executive Director	3.5yrs	US$529.00k	0.058% $ 14.3m
Wai Ling Wong	Company Secretary	8.8yrs	no data	no data

3.5yrs

Average Tenure

55yo

Average Age

Experienced Management: 1548's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 3.3m
Ye Wang	Co-Founder	9yrs	US$615.00k	0.037% $ 9.0m
Fangliang Zhang	co-founder & Executive Director	2yrs	US$271.00k	no data
Li Zhu	Chief Strategy Officer & Executive Director	3.5yrs	US$529.00k	0.058% $ 14.3m
George Church	Member of Advisory Board	4.7yrs	no data	no data
Yuexin Pan	Non-Executive Director	8.8yrs	US$64.00k	0.0027% $ 655.2k
Hong Xin Guo	Independent Non-Executive Director	8.8yrs	US$95.00k	0.0029% $ 717.0k
Zumian Dai	Independent Non-Executive Director	8.8yrs	US$105.00k	no data
Xuehai Wang	Independent Non-Executive Director	3.5yrs	US$120.00k	no data
Luquan Wang	Non-Executive Director	9yrs	no data	0.030% $ 7.4m
Jiuan Pan	Independent Non-Executive Director	5.5yrs	US$124.00k	no data
Jiafen Wang	Non-Executive Director	5.5yrs	US$51.00k	0.00019% $ 47.0k

7.1yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 1548's board of directors are considered experienced (7.1 years average tenure).

Genscript Biotech Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Executive Chairman recently sold HK$610k worth of stock

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated

Key Executive exercised options and sold HK$897k worth of stock

Board Member exercised options and sold HK$1.1m worth of stock

Board Member recently sold HK$2.1m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Co-Founder exercised options and sold HK$93m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Key Executive recently sold HK$9.1m worth of stock

Co-Founder exercised options and sold HK$165m worth of stock

Co-Founder exercised options and sold HK$72m worth of stock

Co-Founder exercised options and sold HK$74m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)